SB17170 Phase 2 Trial in IPF Patients

Summary

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

Timeline

Start

2025-01-27

Primary completion

2026-05-30

Completion

2026-10-31

Drugs

Indications